M. Opsomer

Impact of pharmaceutical intervention on quality of life and coping strategies in patients with haematological malignancies.

F. Bonnetain, D. Caillot, A. Anota, 2016, Annales pharmaceutiques francaises.

No Renal Toxicity After Repeated Treatment with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients with Unresectable Peritoneal Metastasis

C. Rioufol, F. Mercier, O. Glehen, 2018, AntiCancer Research.

Nivolumab-induced organizing pneumonitis in a patient with lung sarcomatoid carcinoma.

G. Zalcman, C. Danel, M. Antoine, 2016, Lung cancer.

Efficacy and safety of rilmenidine in elderly patients—Comparison with hydrochlorothiazide

W. Pelemans, J. Verhaeghe, M. Opsomer, 1994 .

Predictive value of serum alkaline DNase activity variations in treatment of head and neck cancer.

M. Roberfroid, H. Taper, C. Deckers, 1990, Acta oncologica.

Characteristic variations of serum alkaline DNase activity in relation to response to therapy and tumor prognosis in human lung cancer.

M. Roberfroid, H. Taper, M. Opsomer, 1988, European journal of cancer & clinical oncology.

Lazarus syndrome in nonsmall cell lung cancer patients with poor performance status and major leukocytosis following nivolumab treatment

A. Cazes, G. Zalcman, C. Danel, 2017, European Respiratory Journal.

Immune checkpoint inhibitors-related orchitis.

I. Ouzaid, V. Descamps, M. Opsomer, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Systemic and renal haemodynamic effects of angiotensin converting enzyme inhibition by zabicipril in young and in old normal men

R. Naeije, M. Leeman, M. Opsomer, 2004, European Journal of Clinical Pharmacology.